Table 9 The KEGG significantly enriched pathways in the three infective doses (high, medium, and low)
| Â | ID | Description | p.adjust | qvalue | Count |
|---|---|---|---|---|---|
High vs. control | ssc04610 | Complement and coagulation cascades | 8.42E-03 | 8.17E-03 | 12 |
ssc05323 | Rheumatoid arthritis | 2.89E-02 | 2.80E-02 | 12 | |
ssc04657 | IL-17 signaling pathway | 3.37E-02 | 3.27E-02 | 12 | |
Medium vs. control | ssc04060 | Cytokine-cytokine receptor interaction | 4.12E-04 | 3.81E-04 | 24 |
ssc05323 | Rheumatoid arthritis | 4.12E-04 | 3.81E-04 | 14 | |
ssc04061 | Viral protein interaction with cytokine and cytokine receptor | 4.12E-04 | 3.81E-04 | 13 | |
ssc05340 | Primary immunodeficiency | 1.37E-03 | 1.26E-03 | 9 | |
ssc04640 | Hematopoietic cell lineage | 1.40E-03 | 1.29E-03 | 13 | |
ssc05144 | Malaria | 1.68E-03 | 1.56E-03 | 10 | |
ssc04080 | Neuroactive ligand-receptor interaction | 1.80E-02 | 1.66E-02 | 17 | |
ssc04672 | Intestinal immune network for IgA production | 1.80E-02 | 1.66E-02 | 8 | |
ssc05142 | Chagas disease | 1.80E-02 | 1.66E-02 | 13 | |
ssc04657 | IL-17 signaling pathway | 1.80E-02 | 1.66E-02 | 11 | |
ssc04514 | Cell adhesion molecules | 2.28E-02 | 2.11E-02 | 14 | |
Low vs. control | ssc04610 | Complement and coagulation cascades | 5.04E-03 | 4.60E-03 | 3 |
ssc05171 | Coronavirus disease - COVID-19 | 7.38E-03 | 6.73E-03 | 4 | |
ssc04611 | Platelet activation | 1.38E-02 | 1.26E-02 | 3 | |
ssc04613 | Neutrophil extracellular trap formation | 1.38E-02 | 1.26E-02 | 3 |